Time savings of weekly versus three-times-per-week administration of erythropoiesis stimulating agents in United States dialysis patients

References

• Saran R, Li Y, Robinson B. US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 2015;66(1 Suppl 1):S1-306
   Google Scholar
• United States Renal Data System. USRDS ESRD Quarterly Update. July 2015. Available at: http://www.usrds.org/qtr/default.aspx [Last accessed 26 August 2015]
   Google Scholar
• Medicare Payment Advisory Commission (US). Health Care Spending and the Medicare Program: A Data Book June 2015. Washington DC: Medicare Payment Advisory Commission; 2015. Available at: http://www.medpac. gov/documents/data-book/june-2015-databook-health-care-spending-and-the-medicare-program.pdf?sfvrsn=0 [Last accessed 27 August 2015]
   Google Scholar
• United States Renal Data System. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2013
   Google Scholar
• Swaminathan S, Mor V, Mehrotra R, Trivedi A. Medicare’s payment strategy for end-stage renal disease now embraces bundled payment and pay-for-performance to cut costs. Health Aff (Millwood) 2012;31:2051-8
   PubMed Web of Science ®Google Scholar
• Government Printing Office (US). Protecting Access to Medicare Act of 2014. 2014:1061-1062. Available at: http://www.gpo.gov/fdsys/pkg/PLAW-113publ93/pdf/PLAW-113publ93.pdf [Last accessed 28 August 2015]
   Google Scholar
• Stephens JM. Finding consistency in Medicare’s quality ratings for dialysis providers. Nephrol News Issues 2015;29:16-22
   PubMedGoogle Scholar
• Arbor Research Collaborative for Health. DOPPS practice monitor. April 2015. Available at: http://www.dopps.org/DPM/DPMSlideBrowser.aspx [Last accessed 12 August 2015]
   Google Scholar
• McCullough PA, Lepor NE. Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease. Rev Cardiovasc Med 2005;6(Suppl 3):S4-12
   PubMedGoogle Scholar
• Dowling TC. Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: an overview. Am J Health Syst Pharm 2007;64(13 Suppl 8):S3-7
   Google Scholar
• Gilbertson DT, Monda KL, Bradbury BD, Collins AJ. RBC transfusions among hemodialysis patients (1999–2010): influence of hemoglobin concentrations below 10 g/dL. Am J Kidney Dis: 2013;62:919–28 doi:10.1053/j.ajkd.2013.05.004
   Google Scholar
• Sibbel S, Bond TC, Wilfehrt H, et al. Decreased Population Hb Levels and Increased Transfusion Rates Under New ESA Guidelines in Patients with ESRD at an LDO. April 2013. Available at: http://www.davitaclinicalresearch.com/wp-content/pdfs/NKF_2013/Sibbel_Hemoglobin.pdf [Last accessed 1 July 2013]
   Google Scholar
• Schiller B, Doss S, De Cock E, et al. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study. Hemodial Int Int Symp Home Hemodial 2008;12:441-9
   PubMed Web of Science ®Google Scholar
• Schiller B, Besarab A. Simplifying anemia management in hemodialysis patients: ESAs administered at longer dosing intervals can enhance opportunities to provide patient-focused care. Curr Med Res Opin 2011;27:1539-50
   PubMed Web of Science ®Google Scholar
• Barnes RM. Motion and Time Study: Design and Measurement of Work, 7th edn. New York, NY: John Wiley and Sons, 1980. Available at: http://www.wiley.com/WileyCDA/WileyTitle/productCd-0471059056.html [Last accessed 6 April 2015]
   Google Scholar
• Bárány P, Müller H-J. Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease. Nephrol Dial Transplant 2007;22(Suppl 4):iv10-18
   PubMedGoogle Scholar
• Burnier M, Douchamps JA, Tanghe A, et al. Less frequent dosing of erythropoiesis stimulating agents in patients undergoing dialysis: a European multicentre cost study. J Med Econ 2009;12:77-86
   PubMedGoogle Scholar
• De Cock E, Dellanna F, Khellaf K, et al. Time savings associated with C.E.R.A. once monthly: a time-and-motion study in hemodialysis centers in five European countries. J Med Econ 2013;16:648-56
   PubMedGoogle Scholar
• Churchill DN, Macarios D, Attard C, et al. Costs associated with erythropoiesis-stimulating agent administration to hemodialysis patients. Nephron Clin Pract 2007;106:c193-8
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services (US). Renal Cost Reports 265–2011. July 2015. Available at: http://downloads.cms.gov/Files/hcris/RNL11-ALL-YEARS.zip [Last accessed 28 July 2015]
   Google Scholar
• Bureau of Labor Statistics. Occupational Employment Statistics (OES) Data as of May 2014: Outpatient Care Centers, Registered Nurses. April 2015. Available at: http://www.bls.gov/oes/current/naics4_621400.htm#29-0000 [Last accessed 8 April 2015]
   Google Scholar
• Bureau of Labor Statistics. Employment Cost Index – Wages and Salaries for all Civilian Workers in Hospitals, Index. August 2015. Available at: http://data.bls.gov/timeseries/CIU1026220000000I [Last accessed 12 August 2015]
   Google Scholar
• Saueressig U, Kwan JTC, De Cock E, Sapède C. Healthcare resource utilization for anemia management: current practice with erythropoiesis-stimulating agents and the impact of converting to once-monthly C.E.R.A. Blood Purif 2008;26:537-46
   PubMed Web of Science ®Google Scholar
• Bernardo M, Crawford P, Hertel J, et al. Assessment of time and practice resources required to provide weekly or monthly erythropoiesis-stimulating protein therapy to chronic kidney disease patients in the physician office setting. J Manag Care Pharm 2006;12:714-25
   PubMed Web of Science ®Google Scholar
• Ardevol M, Fontsere N, Casals M, et al. A feasibility cost-analysis study of recombinant human erythropoietin and darbepoetin alfa in ambulatory haemodialysis patients during current clinical practice. Eur J Hosp Pharm Sci 2006;12:47-51
   Google Scholar
• Klatko W, Felisiak J. Time and motion study of anaemia management with erythropoiesis stimulating agents in haemodialysis units in Poland. J Health Policy Outcomes Res 2012;1:89-92
   Google Scholar
• De Cock E, Kritikou P, Ravera S, Filippini A. Time savings with once-monthly C.E.R.A.: a time and motion study conducted in 13 haemodialysis centres in Italy. Blood Purif 2015;40:173-9
   PubMed Web of Science ®Google Scholar